Aeras links with new Chinese partner for TB vaccines
This article was originally published in Scrip
Executive Summary
China has been fighting tuberculosis (TB) for decades and is increasingly burdened by the multidrug-resistant form of the mycobacterial infection, which causes nearly 120,000 cases each year or about 25% of the world's total. If no effective treatment is developed, the country will need to spend CNY99 billion ($15.6 billion) to treat 710,000 multidrug-resistant TB patients in the period to 2020, estimates the Beijing-based Chinese Center for Disease Control and Prevention (CCDC).